Substance Use and Substance Use Disorders in a Community Sample of Adolescents and Young Adults: Incidence, Age Effects and Patterns of UsePerkonigg A.a, b · Pfister H.b · Höfler M.b · Fröhlich C.a · Zimmermann P.a · Lieb R.b · Wittchen H.-U.a, b
aDepartment of Clinical Psychology and Psychotherapy, Dresden University of Technology, Dresden, and bDepartment of Clinical Psychology and Epidemiology, Max Planck Institute of Psychiatry, Munich, Germany
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Objective: We present the prevalence and incidence rates of alcohol, nicotine, and illicit substance use, abuse, and dependence in a sample of German adolescents and young adults. Patterns of onset, cohort trends, and use of various substance classes are also analyzed. Method: A prospective longitudinal epidemiological study with a representative sample of adolescents and young adults (n = 3,021; baseline age range = 14–24 years) was conducted in Munich, Germany. Participants were assessed between 1995 and 1999 with the Munich-Composite International Diagnostic Interview. Results: Cumulative lifetime incidence (up to age 28) of any substance abuse or dependence was 43.8%, and 12-month prevalence of any substance abuse or dependence was 24.4%. The lifetime incidence of nicotine dependence was most frequent (24.8%), followed by alcohol abuse (19.3%) and alcohol dependence (9.2%); 61.7% endorsed the regular use of a substance for at least one circumscribed period during their lifetime. Age-specific incidence rates and age at onset of substance use disorders differed by age cohorts. Furthermore, nicotine dependence was significantly associated with illicit substance use disorders (HR = 2.6, 95% CI 1.7–4.0). An interactive relationship between age, age at onset of nicotine dependence, and subsequent onset of illicit substance use disorders was found. Conclusions: Since the baseline investigation in 1995, high incidence rates of substance use disorders and substance use have been observed in this young German sample. Especially younger cohorts report significantly earlier ages at onset of abuse and dependence. There also seems to be a trend towards a secondary age at onset peak of nicotine dependence after the onset of illicit drug use disorders. Further investigations are needed to study these patterns in younger samples. However, results emphasize the need for a combined prevention of illicit drugs and nicotine dependence.
© 2006 S. Karger AG, Basel
- Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8–19.
- Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime Prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593–602.
- Kessler RC, Chiu WT, Demler O, Walters EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617–627.
- Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA: Nicotine dependence and psychiatric disorders in the United States. Arch Gen Psychiatry 2004;61:1107–1115.
- Rehm J, Room R, van den Brink W, Jacobi F: Alcohol use disorders in EU countries and Norway: an overview of the epidemiology. Eur Neuropsychopharmacol 2005;15:377–388.
- Rehm J, Room R, van den Brink W, Kraus L: Problematic drug use and drug use disorders in EU countries and Norway: an overview of the epidemiology. Eur Neuropsychopharmacol 2005;15:389–397.
Armstrong TD, Costello EJ: Community studies on adolescent substance use, abuse, or dependence and psychiatric comorbidity. J Consult Clin Psychol 2002;70:1214–1239.
- Warner LA, Canino G, Colón HM: Prevalence and correlates of substance use disorders among older adolescents in Puerto Rico and the United States: a cross-cultural comparison. Drug Alcohol Depend 2001;63:229–243.
- Young SE, Corley RP, Stallings MC, Rhee SH, Crowley TJ, Hewitt JK: Substance use, abuse and dependence in adolescence: prevalence, symptom profiles and correlates. Drug Alcohol Depend 2002;68:309–322.
Centers for Disease Control and Prevention: Youth Risk Behavior Surveillance – USA, 2003. Atlanta, Centers for Disease Control and Prevention, 2004.
Johnston LD, O’Malley PM, Bachman JG: Monitoring the Future: National Results on Adolescent Drug Use: Overview of Key Findings, 2000. NIH Publication No. 01-4923. Bethesda, National Institute on Drug Abuse, 2001.
European Monitoring Center for Drugs and Drug Addiction: Annual Report 2003: The State of the Drug Problem in the European Union and Norway. Luxembourg, Office for Official Publications of the European Communities, 2003.
Kraus L, Heppekausen K, Barrera A, Orth B: Die Europäische Schülerstudie zu Alkohol and anderen Drogen (ESPAD): Befragung von Schülerinnen und Schülern der 9. und 10. Klasse in Bayern, Berlin, Brandenburg, Hessen, Mecklenburg-Vorpommern und Thüringen. IFT-Berichte Bd 141. München, IFT Institut für Therapieforschung, 2004.
- Nelson CB, Wittchen H-U: Smoking and nicotine dependence. Results from a sample of 14-to 24-year-olds in Germany. Eur Addict Res 1998;4:42–49.
- Holly A, Wittchen H-U: Patterns of use and their relationship to DSM-IV Abuse and Dependence of alcohol among adolescents and young adults. Eur Addict Res 1998;4:50–57.
- Perkonigg A, Lieb R, Wittchen H-U: Prevalence of use, abuse and dependence of illicit drugs among adolescents and young adults in a community sample. Eur Addict Res 1998;4:58–66.
- Sydow K von, Lieb R, Pfister H, Höfler M, Wittchen H-U: What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. Drug Alcohol Depend 2002;68:49–64.
- Sydow K von, Lieb R, Pfister H, Höfler M, Wittchen H-U: Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults – a transient phenomenon? Results from a longitudinal community study. Drug Alcohol Depend 2002;66:147–159.
- Wittchen H-U, Perkonigg A, Lachner G, Nelson CB: The Early Development Stages of Psychopathology Study (EDSP) – objectives and design. Eur Addict Res 1998;4:18–27.
- Lieb R, Isensee B, von Sydow K, Wittchen H-U: The early development stages of psychopathology study (EDSP): a methodological update. Eur Addict Res 2000;6:170–182.
Wittchen H-U, Pfister H (eds): DIA-X-Interviews: Manual für Screening-Verfahren und Interview. Interviewheft Längsschnittuntersuchung (DIA-X-Lifetime); Ergänzungsheft (DIA-X lifetime); Interviewheft Querschnittuntersuchung (DIA-X 12 Monate); Ergänzungsheft (DIA-X 12 Monate); PC-Programm zur Durchführung des Interviews (Längs- und Querschnittuntersuchung); Auswertungsprogramm. Frankfurt, Swets & Zeitlinger, 1997.
- Wittchen H-U, Lachner G, Wunderlich U, Pfister H: Test-retest reliability of the computerized DSM-IV-version of the Munich-Composite International Diagnostic Interview (M-CIDI). Soc Psychiatry Psychiatr Epidemiol 1998;33:568–578.
Reed V, Gander F, Pfister H, Steiger A, Sonntag H, Trenkwalder C, Hundt W, Wittchen HU: To what degree the Composite International Diagnostic Interview (CIDI) correctly identifies DSM-IV disorders? Testing validity issues in a clinical sample. Int J Methods Psychiatr Res 1998;7:142–155.
- Lachner G, Wittchen HU, Perkonigg A, et al: Structure, content, and reliability of the Munich Composite Diagnostic Interview (M-CIDI) substance use sections. Eur Addict Res 1998;4:28–41.
Stata Corp: Stata Statistical Software: Release 6.0. College Station, Stata Corp, 1999.
Therneau TM, Grambsch PM: Modeling Survival Data – Extending the Cox Model. New York, Springer, 2000.
- Perkonigg A, Lieb R, Wittchen H-U: Substance use, abuse and dependence in Germany: a review of selected epidemiological data. Eur Addict Res 1998;4:8–17.
- Hanson KL, Luciana M: Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use. Psychol Med 2004;34:229–246.
Perkonigg A, Pfister H, Lieb R, Bühringer G, Wittchen HU: Problematic use of illicit substances, help-seeking and the availability of substance use services in a region (in German). Suchtmed 2004;6:22–31.
Department of Health: Drug Use, Smoking and Drinking among Young People in England in 2003. London, National Centre for Social Research, 2004.
- Degenhardt L, Lynskey M, Hall W: Cohort trends in the age of initiation of drug use in Australia. Aust NZ J Public Health 2000;24:421–426.
- Grant BF, Dawson D: Age of onset of drug use and its association with DSM-IV drug abuse and dependence: Results from the National Longitudinal Alcohol Epidemiologic Survey. J Subst Abuse 1998;10:163–173.
- Chen C-Y, Anthony JC: Possible age-associated bias in reporting of clinical features of drug dependence: epidemiological evidence on adolescent-onset marijuana use. Addiction 2003;98:71–82.
- Nocon A, Wittchen HU, Pfister H, Zimmermann P, Lieb R: Dependence symptoms in young cannabis users? A prospective epidemiological study. J Psychiatr Res 2006;40:394–403.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.